Novo Nordisk A/S (LON:0QIU)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 154.98B -7.2% |
| Revenue (ttm) | 38.30B +8.1% |
| Net Income | 14.25B +16.6% |
| EPS | 3.20 +16.8% |
| Shares Out | n/a |
| PE Ratio | 10.88 |
| Forward PE | 15.29 |
| Dividend | 1.37 (3.65%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 1,174,100 |
| Open | 329.08 |
| Previous Close | 332.44 |
| Day's Range | 295.95 - 333.70 |
| 52-Week Range | 224.55 - 409.90 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?
Novo Nordisk ($NVO) shares dropped about 9% today after the company reported that its experimental heart drug ziltivekimab failed a major Phase 3 clinical trial. TD Cowen called the failed…
A Look at Novo Nordisk AS (NVO) After 8.8% Decline -- GF Value $139.61 vs Price $47.08
A Look at Novo Nordisk AS (NVO) After 8.8% Decline -- GF Value $139.61 vs Price $47.08
Mizuho's Holz talks Novo Nordisk shares tumbling after its heart medicine fails trial
Jared Holz, Mizuho Securities Healthcare Sector Specialist, joins 'Fast Money' to talk Novo's heart medicine trial.
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?
Shares of Danish drugmaker Novo Nordisk fell nearly 10% today. The drop came after an experimental cardiovascular drug failed a late-stage clinical trial.
Monte Rosa Therapeutics (GLUE) Shares Drop Amid Novo Nordisk Trial Failure; P/S Valuation Under ...
Monte Rosa Therapeutics (GLUE) Shares Drop Amid Novo Nordisk Trial Failure; P/S Valuation Under Scrutiny
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
Monte Rosa Therapeutics (GLUE) is trading lower after Novo Nordisk’s (NVO) ZEUS trial failed to show a cardiovascular benefit for IL 6 inhibition, a readout that dampens sentiment around inflammation…
BioAge Labs price target lowered to $25 from $36 at Roth Capital
Roth Capital analyst Adam Walsh lowered the firm’s price target on BioAge Labs (BIOA) to $25 from $36 and keeps a Buy rating on the shares after Novo Nordisk’s (NVO)…
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
Jefferies lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $25 from $40 and keeps a Buy rating on the shares after Novo Nordisk’s (NVO) ZEUS study of…
European Stocks Retreat as Novo Nordisk (NVO) and Universal Music (UMG) Weigh Down Market
European Stocks Retreat as Novo Nordisk (NVO) and Universal Music (UMG) Weigh Down Market
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
Citi notes that BioAge Labs (BIOA) shares are down greater than 60% following the news that Novo Nordisk’s (NVO) ZEUS trial for ziltivekimab failed to demonstrate a benefit on MACE.
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obesity segment.
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced selling pressure on Friday.
Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting ...
Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial
The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.
Novo Nordisk's stock slumps after failed trial — adding to the company's woes
The Danish healthcare company's stock slumped on Friday after it announced the Phase 3 trial failure.
Novo Nordisk (NVO) Faces 10% Stock Drop After Heart Drug Trial Results
Novo Nordisk (NVO) Faces 10% Stock Drop After Heart Drug Trial Results
Novo Nordisk Suffers Another Pipeline Setback
Novo Nordisk Suffers Another Pipeline Setback
Novo Nordisk Stock Falls 7% as ZEUS Trial Fails
Novo Nordisk Stock Falls 7% as ZEUS Trial Fails
Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results
U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year. They look likely to drop into the red today.
Novo Nordisk's ZEUS Trial Shows No Cardiovascular Event Reduction Despite IL-6 Pathway Success
(RTTNews) - Novo Nordisk A/S (NVO) has released results from its pivotal Phase 3 ZEUS trial, which tested the investigational therapy Ziltivekimab in people with atherosclerotic cardiovascular disease...
Novo Nordisk Stock (NVO) Plunges 10% as Weight-Loss Drug Trial Disappoints
Shares of Novo Nordisk ($NVO) are down 10% on July 31 after the European pharmaceutical giant reported disappointing results from its latest weight-loss drug trial.
Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial
Stock was down 9.5% after the company's experimental medicine ziltivekimab didn't achieve the expected risk reduction for major cardiovascular events.
Novo Nordisk reports ziltivekimab did not yield MACE benefits in ZEUS study
Novo Nordisk (NVO) announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by...
Novo Nordisk down 10% after ZEUS cardiovascular outcomes study misses goal
Shares of Novo Nordisk (NVO) are down $5.19, or 10%, to $46.39 in pre-market trading in New York.
Novo Nordisk shares dive 9% after heart medicine fails trial
Novo Nordisk shares dive 9% after heart medicine fails trial